Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

BMEA

Biomea Fusion Inc

May 31 • 04:00PM ET

10.52

Dollar change +0.06
Percentage change 0.57	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM LABU VXF IBB IWO SCHA VHT VTWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.56	Insider Own	22.61%	Shs Outstand	35.87M	Perf Week	-5.48%
Market Cap	378.09M	Forward P/E	-	EPS next Y	-3.84	Insider Trans	0.00%	Shs Float	27.82M	Perf Month	-9.08%
Income	-127.27M	PEG	-	EPS next Q	-1.07	Inst Own	88.06%	Short Float	47.23%	Perf Quarter	-40.93%
Sales	0.00M	P/S	-	EPS this Y	-19.74%	Inst Trans	-10.86%	Short Ratio	13.08	Perf Half Y	-17.49%
Book/sh	3.77	P/B	2.79	EPS next Y	6.80%	ROA	-90.54%	Short Interest	13.14M	Perf Year	-69.02%
Cash/sh	4.03	P/C	2.61	EPS next 5Y	-	ROE	-116.52%	52W Range	8.12 - 43.69	Perf YTD	-27.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-204.86%	ROI	-88.85%	52W High	-75.92%	Beta	-0.37
Dividend TTM	-	Quick Ratio	5.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	29.48%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	5.84	EPS Y/Y TTM	-10.86%	Oper. Margin	0.00%	RSI (14)	40.58	Volatility	7.76% 7.26%
Employees	103	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.38	Target Price	48.25
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-10.84%	Payout	-	Rel Volume	0.82	Prev Close	10.46
Sales Surprise	-	EPS Surprise	-9.64%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	1.00M	Price	10.52
SMA20	-10.32%	SMA50	-15.22%	SMA200	-24.87%	Trades		Volume	823,592	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral	$51 → $14
Feb-06-24	Initiated	Truist	Buy	$55
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$41
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight	$50
Mar-29-23	Reiterated	Oppenheimer	Outperform	$25 → $47
Mar-28-23	Reiterated	H.C. Wainwright	Buy	$37 → $44
Feb-24-23	Initiated	Citigroup	Buy	$20
Jun-02-22	Resumed	H.C. Wainwright	Buy	$16
Jan-12-22	Initiated	H.C. Wainwright	Buy	$13
Dec-17-21	Initiated	Oppenheimer	Outperform	$22
May-11-21	Initiated	Piper Sandler	Overweight	$27
May-11-21	Initiated	JP Morgan	Overweight	$26
May-11-21	Initiated	Jefferies	Buy	$26

Show Previous Ratings

May-30-24 09:12AM	Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes (GlobeNewswire)
May-02-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Apr-19-24 11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
04:10PM	Loading…
Apr-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:52PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023 (InvestorPlace)
09:02AM	Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219 (GlobeNewswire)
09:00AM	Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-07-24 02:52PM	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode (InvestorPlace)
Mar-06-24 03:04AM	Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function (GlobeNewswire) -9.82%
Mar-01-24 04:16PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-24 03:18PM	Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For (InvestorPlace)
Feb-18-24 03:41PM	3 Speculative Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 04:19PM	3 Long-Term Stocks to Buy on the Dip: February 2024 (InvestorPlace)
11:02AM	Loading…
Jan-09-24 11:02AM	Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-24 09:00AM	Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219 (GlobeNewswire) +8.36%
Jan-02-24 04:05PM	Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 09:27AM	Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why (Zacks) +15.29%
Dec-11-23 09:25AM	Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting (GlobeNewswire) -30.31%
Dec-09-23 05:30PM	Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts (GlobeNewswire)
Dec-08-23 09:00AM	Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) +12.38%
Dec-07-23 09:15AM	Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -18.54%
Dec-05-23 08:30AM	Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Nov-27-23 08:30AM	Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024 (GlobeNewswire)
Nov-16-23 08:30AM	Biomea Fusion Abstract BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control' Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (GlobeNewswire)
Nov-08-23 04:05PM	Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Nov-02-23 09:05AM	Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023 (GlobeNewswire)
Nov-01-23 05:58AM	Biomea Fusion Inc (BMEA) Reports Q3 2023 Financial Results and Corporate Highlights (GuruFocus.com)
Oct-31-23 01:19AM	The Biomea Fusion Inc (BMEA) Company: A Short SWOT Analysis (GuruFocus.com) -7.59%
04:01PM	Loading…
Oct-30-23 04:01PM	Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-18-23 10:13AM	Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up (Zacks)
Oct-17-23 08:30AM	Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103) (GlobeNewswire) +6.72%
Oct-05-23 09:40AM	Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Sep-28-23 08:30AM	Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study (GlobeNewswire)
Aug-31-23 08:30AM	Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer (GlobeNewswire)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Jul-31-23 04:01PM	Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-24-23 09:00AM	BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population (GlobeNewswire) -14.58%
Jul-13-23 10:08AM	We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-26-23 10:54AM	Biomea Fusion Stock Is Trading Higher Today - Here's Why (Benzinga) -20.39%
Jun-23-23 09:54PM	Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment (GlobeNewswire) -5.89%
Jun-20-23 04:30PM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023 (GlobeNewswire)
Jun-05-23 06:44AM	Daily Vickers Top Buyers & Sellers for 06/05/2023 (Argus Research)
May-18-23 06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia)
May-02-23 04:01PM	Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) -8.55%
May-01-23 08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia (GlobeNewswire) +7.60%
Apr-27-23 07:02AM	Daily Vickers Top Buyers & Sellers for 04/27/2023 (Argus Research) -8.20%
Apr-23-23 09:28AM	individual investors who own 31% along with institutions invested in Biomea Fusion, Inc. (NASDAQ:BMEA) saw increase in their holdings value last week (Simply Wall St.)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia) +5.77%
08:30AM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June (GlobeNewswire)
Apr-13-23 04:30PM	Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting (GlobeNewswire)
09:00AM	Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-07-23 07:44AM	Daily Vickers Top Buyers & Sellers for 04/07/2023 (Argus Research)
Mar-30-23 02:35PM	Why Biomea Fusion Stock Crushed It This Week (Motley Fool)
Mar-29-23 11:15PM	Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +5.34%
12:01PM	Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study (Zacks)
11:24AM	Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback (Zacks)
06:30AM	Biomea Fusion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-28-23 04:02PM	Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) +99.03%
08:00AM	Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28 (GlobeNewswire)
Mar-23-23 08:00AM	Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET (GlobeNewswire) +5.26%
Mar-21-23 09:40AM	Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-20-23 08:50AM	What Makes Biomea Fusion, Inc. (BMEA) a Good Fit for 'Trend Investing' (Zacks)
Mar-02-23 08:30AM	Biomea Fusion To Participate In Upcoming Investor Events (GlobeNewswire) -8.13%
Jan-20-23 11:30AM	Why Shares of Biomea Fusion Jumped This Week (Motley Fool) +7.44%
Jan-18-23 11:27AM	Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up (Zacks) +13.00%
Jan-17-23 08:00AM	Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors (GlobeNewswire) +11.69%
Jan-09-23 08:00AM	Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones (GlobeNewswire)
Jan-04-23 09:00AM	Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219 (GlobeNewswire) -9.67%
Dec-14-22 04:30PM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes (GlobeNewswire)
05:44AM	Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation (Simply Wall St.)
Dec-12-22 08:00AM	Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date (GlobeNewswire)
Nov-14-22 08:12AM	Institutional owners may take dramatic actions as Biomea Fusion, Inc.'s (NASDAQ:BMEA) recent 29% drop adds to one-year losses (Simply Wall St.)
Nov-11-22 08:30AM	Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -6.17%
Nov-07-22 04:27PM	Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) -10.17%
Nov-03-22 09:19AM	Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219 (GlobeNewswire) +7.00%
Oct-27-22 08:00AM	Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial (GlobeNewswire)
Oct-14-22 09:00AM	BMF-219 Enters the Clinic for KRAS Solid Tumors (GlobeNewswire)
Sep-22-22 09:30AM	Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Sep-20-22 07:30AM	Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Sep-19-22 12:01PM	Despite Biomea Fusion, Inc.'s recent decline, insiders have made a around US$30k profit after buying earlier this year. (Simply Wall St.)
Aug-26-22 01:13PM	Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate (Benzinga)
08:30AM	Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting (GlobeNewswire)
Aug-01-22 04:05PM	Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Jul-06-22 02:41PM	Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation (Simply Wall St.)
Jul-01-22 08:30AM	Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes (GlobeNewswire) -6.93%
Jun-22-22 08:30AM	Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial (GlobeNewswire) +13.97%
Jun-06-22 01:10PM	How Much Of Biomea Fusion, Inc. (NASDAQ:BMEA) Do Institutions Own? (Simply Wall St.)
Jun-04-22 11:00AM	Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Jun-02-22 06:00PM	Biomea Fusion to Participate in Jefferies Healthcare Conference (GlobeNewswire) +7.64%
Jun-01-22 08:30AM	Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022 (GlobeNewswire) -18.94%
May-26-22 06:30PM	Biomea Fusion to Present New Preclinical Data Showing BMF-219s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022 (GlobeNewswire)
May-20-22 01:30PM	Biomea Fusion to Attend H.C. Wainwright Global Investment Conference (GlobeNewswire) +8.46%
May-19-22 08:00AM	Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3 (GlobeNewswire) +16.18%
May-16-22 07:30AM	Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMEA

Biomea Fusion Inc

Upgrade your FINVIZ experience